Integra LifeSciences Stock Forecast, Price & News

Integra LifeSciences (NASDAQ:IART) Frequently Asked Questions

Is Integra LifeSciences a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Integra LifeSciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IART, but not buy additional shares or sell existing shares.
View analyst ratings for Integra LifeSciences or view top-rated stocks.

What stocks does MarketBeat like better than Integra LifeSciences?

Wall Street analysts have given Integra LifeSciences a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Integra LifeSciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Integra LifeSciences' next earnings date?

Integra LifeSciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Integra LifeSciences.

How can I listen to Integra LifeSciences' earnings call?

Integra LifeSciences will be holding an earnings conference call on Tuesday, November 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 888-203-1112 with passcode "7732018".

How were Integra LifeSciences' earnings last quarter?

Integra LifeSciences Holdings Co. (NASDAQ:IART) posted its earnings results on Tuesday, July, 27th. The life sciences company reported $0.79 EPS for the quarter, beating analysts' consensus estimates of $0.66 by $0.13. The life sciences company had revenue of $389.99 million for the quarter, compared to analysts' expectations of $376.11 million. Integra LifeSciences had a net margin of 13.62% and a trailing twelve-month return on equity of 17.64%.
View Integra LifeSciences' earnings history.

How has Integra LifeSciences' stock price been impacted by Coronavirus (COVID-19)?

Integra LifeSciences' stock was trading at $46.08 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IART stock has increased by 53.7% and is now trading at $70.82.
View which stocks have been most impacted by COVID-19.

When did Integra LifeSciences' stock split? How did Integra LifeSciences' stock split work?

Integra LifeSciences shares split on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly issued shares were payable to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of Integra LifeSciences stock prior to the split would have 200 shares after the split.

What guidance has Integra LifeSciences issued on next quarter's earnings?

Integra LifeSciences issued an update on its FY 2021 earnings guidance on Wednesday, August, 4th. The company provided earnings per share guidance of $2.980-$3.050 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.920. The company issued revenue guidance of $1.54 billion-$1.55 billion, compared to the consensus revenue estimate of $1.53 billion.

What price target have analysts set for IART?

7 brokers have issued 12 month price targets for Integra LifeSciences' stock. Their forecasts range from $65.00 to $88.00. On average, they expect Integra LifeSciences' stock price to reach $75.75 in the next twelve months. This suggests a possible upside of 7.0% from the stock's current price.
View analysts' price targets for Integra LifeSciences or view top-rated stocks among Wall Street analysts.

Who are Integra LifeSciences' key executives?

Integra LifeSciences' management team includes the following people:

• Peter J. Arduini, President, Chief Executive Officer & Director
• Glenn G. Coleman, Chief Operating Officer & Executive Vice President (LinkedIn Profile)
• Carrie Anderson, Chief Financial Officer, Treasurer & Executive VP
• William Compton, Chief Information Officer & Senior Vice President
• Kenneth E. Burhop, Chief Scientific Officer & Vice President

What is Peter J. Arduini's approval rating as Integra LifeSciences' CEO?

173 employees have rated Integra LifeSciences CEO Peter J. Arduini on Glassdoor.com. Peter J. Arduini has an approval rating of 74% among Integra LifeSciences' employees.

Who are some of Integra LifeSciences' key competitors?

Some companies that are related to Integra LifeSciences include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Edwards Lifesciences (EW), Becton, Dickinson and (BDX), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), Baxter International (BAX), ResMed (RMD), STERIS (STE), Insulet (PODD), Hologic (HOLX) and Teleflex (TFX).
View all of IART's competitors.

What other stocks do shareholders of Integra LifeSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra LifeSciences investors own include The Boeing (BA), NVIDIA (NVDA), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Marvell Technology (MRVL), Alexion Pharmaceuticals (ALXN) and Abbott Laboratories (ABT).

What is Integra LifeSciences' stock symbol?

Integra LifeSciences trades on the NASDAQ under the ticker symbol "IART."

Who are Integra LifeSciences' major shareholders?

Integra LifeSciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Tributary Capital Management LLC (0.48%), Strs Ohio (0.10%), Nisa Investment Advisors LLC (0.10%), Exchange Traded Concepts LLC (0.06%), Virginia Retirement Systems ET AL (0.04%) and State of Alaska Department of Revenue (0.03%). Company insiders that own Integra LifeSciences stock include Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, Lisa Evoli, Peter J Arduini, Raymond G Murphy, Richard E Caruso, Stuart Essig and Tru St Partnership, LP.
View institutional ownership trends for Integra LifeSciences.

Which institutional investors are selling Integra LifeSciences stock?

IART stock was sold by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, Tributary Capital Management LLC, Oregon Public Employees Retirement Fund, and Pacer Advisors Inc.. Company insiders that have sold Integra LifeSciences company stock in the last year include Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, Lisa Evoli, Raymond G Murphy, Stuart Essig, and Tru St Partnership, LP.
View insider buying and selling activity for Integra LifeSciences or view top insider-selling stocks.

Which institutional investors are buying Integra LifeSciences stock?

IART stock was bought by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Virginia Retirement Systems ET AL, State of Alaska Department of Revenue, Private Advisor Group LLC, Koshinski Asset Management Inc., Strs Ohio, Campbell Newman Asset Management Inc., and Louisiana State Employees Retirement System.
View insider buying and selling activity for Integra LifeSciences or or view top insider-buying stocks.

How do I buy shares of Integra LifeSciences?

Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Integra LifeSciences' stock price today?

One share of IART stock can currently be purchased for approximately $70.82.

How much money does Integra LifeSciences make?

Integra LifeSciences has a market capitalization of $5.99 billion and generates $1.37 billion in revenue each year. The life sciences company earns $133.89 million in net income (profit) each year or $2.45 on an earnings per share basis.

How many employees does Integra LifeSciences have?

Integra LifeSciences employs 3,700 workers across the globe.

What is Integra LifeSciences' official website?

The official website for Integra LifeSciences is www.integralife.com.

Where are Integra LifeSciences' headquarters?

Integra LifeSciences is headquartered at 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536.

How can I contact Integra LifeSciences?

Integra LifeSciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at (609) 275-0500 or via email at [email protected].